{
    "clinical_study": {
        "@rank": "35104", 
        "arm_group": [
            {
                "arm_group_label": "IMC-1", 
                "arm_group_type": "Experimental", 
                "description": "Experimental intervention"
            }, 
            {
                "arm_group_label": "Matching placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate\n      the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia\n      symptoms or recurrence.  IMC-1 is a combination treatment that is designed to suppress this\n      suspected virus and thus alleviate fibromyalgia symptoms."
        }, 
        "brief_title": "A Study of IMC-1 In Patients With Fibromyalgia", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Fibromyalgia", 
            "Chronic Pain", 
            "Myofascial Pain"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fibromyalgia", 
                "Myofascial Pain Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of fibromyalgia\n\n          -  English speaker\n\n        Exclusion Criteria:\n\n          -  Rheumatologic diseases\n\n          -  Bipolar disease, OCD, severe anxiety, schizophrenia\n\n          -  Systemic infection, severe cardiac disease, chronic steroid usage\n\n          -  chronic opioid usage"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850420", 
            "org_study_id": "PRID-201"
        }, 
        "intervention": {
            "arm_group_label": "IMC-1", 
            "intervention_name": "IMC-1", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "fibromyalgia", 
            "Myofascial"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vista", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evansville", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Medford", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "IMC Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }, 
                    "name": "IMC Study Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Comparison of the change from baseline in patient self reported pain scores between IMC-1 and placebo treatment, over 16 weeks of treatment", 
            "measure": "Change in pain from baseline", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850420"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients will rate their global improvement over the duration of the trial", 
                "measure": "Patient Global Impression of Change", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Fibromyalgia Impact Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "Innovative Med Concepts, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Innovative Med Concepts, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}